CN101390973A - Use of traditional Chinese medicine in preparing medicine for treating retinal vein obstruction - Google Patents
Use of traditional Chinese medicine in preparing medicine for treating retinal vein obstruction Download PDFInfo
- Publication number
- CN101390973A CN101390973A CNA2007101522460A CN200710152246A CN101390973A CN 101390973 A CN101390973 A CN 101390973A CN A2007101522460 A CNA2007101522460 A CN A2007101522460A CN 200710152246 A CN200710152246 A CN 200710152246A CN 101390973 A CN101390973 A CN 101390973A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- lignum
- traditional chinese
- retinal vein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a traditional Chinese medicine composite which is applied to preparing the medicine for curing retinal vein occlusion. The traditional chinese medicine composite is composed of ginseng, leech, centipede, scorpion, woodlouse, cicada slough, red peony root and borneol and the like, with efficiency of supplementing qi and activating blood circulation and eliminating blood stasis and freeing channels. The traditional chinese medicine composite has the function of osmosis resistance, strengthening the venous constriction, improving the flexibility of the vein wall, and increasing the venous pressure of the blood vessel wall, so as to reach the detumescence and relief purpose for vein blood stasis symptom, alleviate retinal edema and the edema in blood vessels, strengthen retinal artery blood supplying and improve the sight of patients who have retinal vein occlusion. The traditional chinese medicine composite has obvious curative effects on curing the retinal vein occlusion, and the total curative effect ratio which is validated in clinical trials of curing the retinal vein occlusion through the traditional chinese medicine composite can reach 91.9%, with security and simplicity and few adverse effects.
Description
Technical field
The present invention relates to a kind of new purposes of Chinese medicine composition, particularly, the present invention relates to the application of a kind of Chinese medicine composition in the medicine of the preparation treatment retinal vein occlusion, belong to the Chinese medicine application.
Background technology
The retinal vein occlusion (RVO) but be a kind of serve as the main blinding retinopathy that changes with the tortuous expansion of retinal vein and the venous drainage district retinal hemorrhage of getting involved, edema, ooze out etc.Its clinical manifestation is: visual deterioration, papilla of optic nerve hyperemia, edema can be arranged, and obscurity boundary, centration, flamboyancy, wire retina superficial hemorrhage and point-like, ecchymosis appear in full retinal edema; Retinal vein is expanded to some extent, is twisted, view reflection,arterial constriction; Edema and rigid oozing out can appear in macula lutea, and back utmost point portion retina also the velveteen speckle can occur; Continue development as pathological changes, the optical fundus new vessels can occur,, visual function is further descended, also can cause neovascular glaucoma and lose one's sight because new vessels is very easily hemorrhage.Its cause of disease complexity, the course of disease is longer, and complication is more, treats thornyly, and its blind rate is 15.9%.[the Huang Quanren chief editor. clinical retinopathy is learned. Hefei: Anhui science and technology publishing house.1994]
Great mass of data shows: owing to the stasis of EV compressing, venous blood and the infringement of vein blood vessel inwall cause with hypertension, arteriosclerosis, hyperlipidemia, blood high viscosity, abnormal hemodynamics, retinal vasculitis and diabetes etc. substantial connection is arranged.Because of its cause of disease complexity, the course of disease is longer, and the complication of generation is more, and its treatment is a difficult problem all the time.There is not Therapeutic Method very preferably at present clinically.[Zhang Huirong, the pathogenic risk factor and the Visual outcome [J] of the Xia Yingjie .407 example retinal vein occlusion. Chinese Journal of Ophthalmology, 1991,27 (5): 271-274.]
Primary disease is similar to Chinese medicine sudden blindness (syndrome of blood stasis), no matter diseases caused by exogenous pathogenic factor, internal injury or because of empty, because of reality, all be because QI-blood circulation is slow, blood stasis eye network, the stasis of blood stagnates obstructed, blocks sering, outside the blockage of vessel blood oozing from the body openings or subcuta neous tissue arteries and veins, blood circulating out of vessels forms the stasis of blood.Blood stasis runs through the course of disease all the time.
The present invention is the improvement invention of carrying out on the basis of No. 01131203.3 and No. 200410048292.2 patent, quotes in full the content of this two patent documents record at this.Unexposed this Chinese medicine composition of above-mentioned two patents is in the application of the treatment retinal vein occlusion.The present invention has carried out correlational study on its basis, and the application of this Chinese medicine composition in the medicine of the preparation treatment retinal vein occlusion is provided.
Summary of the invention
The object of the invention provides the application of a kind of Chinese medicine composition in the medicine of the preparation treatment retinal vein occlusion, and described Chinese medicine composition is made by following bulk drugs:
Radix Ginseng 3-10 Hirudo 3-11 Eupolyphaga Seu Steleophaga 5-10 Olibanum (system) 1-5 Radix Paeoniae Rubra 3-9 Lignum Dalbergiae Odoriferae 1-5
Lignum Santali Albi 1-5 Scorpio 3-9 Periostracum Cicadae 3-12 Scolopendra 1-3 Borneolum Syntheticum 1-7 Semen Ziziphi Spinosae (stir-fry) 3-10;
Preferably, this Chinese medicine composition is made by following bulk drugs:
Radix Ginseng 6 Hirudo 10 Eupolyphaga Seu Steleophagas, 7 Olibanums (system) 2 Radix Paeoniae Rubra 5 Lignum Dalbergiae Odoriferaes 2
Lignum Santali Albi 2 Scorpios 7 Periostracum Cicadaes 7 Scolopendra 1 Borneolum Syntheticum, 5 Semen Ziziphi Spinosaes (stir-fry) 5;
Or:
Radix Ginseng 10 Hirudo 8 Eupolyphaga Seu Steleophagas, 7 Olibanums (system) 2 Radix Paeoniae Rubra 5 Lignum Dalbergiae Odoriferaes 2
Lignum Santali Albi 2 Scorpios 9 Periostracum Cicadaes 7 Scolopendra 1 Borneolum Syntheticum, 5 Semen Ziziphi Spinosaes (stir-fry) 5;
Or:
Radix Ginseng 6 Hirudo 11 Eupolyphaga Seu Steleophagas, 7 Olibanums (system) 2 Radix Paeoniae Rubra 5 Lignum Dalbergiae Odoriferaes 2
Lignum Santali Albi 2 Scorpios 3 Periostracum Cicadaes 7 Scolopendra 1 Borneolum Syntheticum, 5 Semen Ziziphi Spinosaes (stir-fry) 5;
More preferably, the active component of above-mentioned Chinese medicine composition is made up of following ingredients:
The a mean diameter is less than Scorpio, Hirudo, Scolopendra, Eupolyphaga Seu Steleophaga, Periostracum Cicadae and the Olibanum (processed) medicated powder of 100 μ m;
B Borneolum Syntheticum medicated powder;
The volatile oil that c is extracted by Lignum Dalbergiae Odoriferae and Lignum Santali Albi;
The alcohol-extracted extract of the alcohol extract of d Radix Ginseng after after concentrating with ethanol extraction;
The water extracted immersing paste that is condensed into behind the water extract after the Lignum Dalbergiae Odoriferae behind the e extraction composition c and water extract, Radix Paeoniae Rubra and the Semen Ziziphi Spinosae (parched) of Lignum Santali Albi medicinal residues decoct with water and the water extract filtration of the medicine residues of Radix Ginseng after the extraction ingredient d, the mixing.
The invention also discloses that to contain above-mentioned Chinese medicine composition be capsule, tablet, granule, powder, oral liquid or pill as the pharmaceutical preparation of active component.
The present invention also provides the application in the medicine that this Chinese medicine composition preparation improves retinal vein occlusion patient's vision.
In the Chinese medicine composition of the present invention, as the latin name of the crude drug of active component and processing method thereof from " Chinese medicine voluminous dictionary " (in July, 1977, front page, Shanghai science tech publishing house) and " Chinese pharmacopoeia (version in 2005, Chemical Industry Press).
Chinese medicine composition of the present invention can also be routinely extraction and preparation process, for example, the preparation technology of Fan Biting " pharmacy of Chinese materia medica " (Shanghai Science Press 1997 December the 1st edition) record, make the acceptable any conventional dosage form of pharmaceutics, for example capsule, tablet, granule, powder, oral liquid or pill etc.
In the application of the present invention, described Chinese medicine composition is a kind of in capsule, tablet, granule, powder, oral liquid or the pill preparation, for above-mentioned dosage form can be realized, need when these dosage forms of preparation, to add the pharmacy acceptable auxiliary, for example: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic, substrate etc.Filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc.; Disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc.; Lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc.; Suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc.; Binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc.; Sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc.; Correctives comprises: sweeting agent and various essence; Antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, fixed, the Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods of acetic acid chloroethene; Substrate comprises: PEG6000, PEG4000, insect wax etc.
Preparation of the present invention is preferably made by following preparation method: five kinds of Chinese medicine such as the Hirudo of said ratio, Scorpio, Periostracum Cicadae, Eupolyphaga Seu Steleophaga, Scolopendra cleaned, and oven drying at low temperature, standby; Lignum Santali Albi, Lignum Dalbergiae Odoriferae extract volatile oil, and medicinal residues and aqueous solution are standby; Radix Ginseng extracts secondary with 70% alcohol heating reflux, and 3 hours for the first time, 2 hours for the second time, merge extractive liquid, reclaimed ethanol to there not being the alcohol flavor; The medicinal residues of medicine residues of Radix Ginseng and Lignum Santali Albi, Lignum Dalbergiae Odoriferae merge with aqueous solution, add Radix Paeoniae Rubra, Semen Ziziphi Spinosae (stir-fry), decoct with water secondary, 3 hours for the first time, 2 hours for the second time, collecting decoction filters, and filtrate is concentrated into the clear paste that relative density is 1.20-1.25 (60 ℃), add above-mentioned panaxynol extract, mixing, cold drying is ground into fine powder; The five tastes such as Olibanum (system) and Hirudo are ground into fine powder altogether; The Borneolum Syntheticum porphyrize, with above-mentioned fine powder facing-up, mixing sprays into volatile oil respectively, and mixing incapsulates, promptly.
Perhaps, preparation of the present invention is preferably made by following preparation method:
A) weight ratio of crude drug is: Radix Ginseng 3-10 part, Hirudo 3-11 part, Eupolyphaga Seu Steleophaga 5-10 part, Olibanum (processed) 1-5 part, Radix Paeoniae Rubra 3-9 part, Lignum Dalbergiae Odoriferae 1-5 part, Lignum Santali Albi 1-5 part, Scorpio 3-9 part, Periostracum Cicadae 3-12 part, Scolopendra 1-3 part, Borneolum Syntheticum 1-7 part, Semen Ziziphi Spinosae (parched) 3-10 part;
B) pulverizing medicinal materials technology:
Scorpio, Hirudo, Scolopendra, Eupolyphaga Seu Steleophaga and five kinds of worm medicines of Periostracum Cicadae are prepared burden by prescription through the Olibanum (processed) that cleans, washes after handling the back and cleaning the process of preparing Chinese medicine, pulverized by pulverizer, the medicated powder fineness reaches more than 80 orders; Medicated powder behind the coarse powder carries out micronizing through various superfine communication techniques, makes the medicated powder mean diameter less than 100 μ m; Medical material to be pulverized is prepared burden after the cleaning, drying sterilization;
C) extract concentrated and drying process:
Reuse water extraction behind Lignum Dalbergiae Odoriferae and the Lignum Santali Albi elder generation extracting in water volatile oil, Radix Paeoniae Rubra and Semen Ziziphi Spinosae decoct with water, after the water extract filters, extractum to be condensed into; Radix Ginseng with ethanol extraction after, reuse water extraction, alcohol extract are condensed into alcohol-extracted extract after reclaiming ethanol, the water extract filter with all water extract mixings after be condensed into the water extracted immersing paste;
D) preparation process:
In Fluidbedgranulatingdrier, add the superfine powder flour, again the step c) gained is extracted extractum and spray into granulation; The granule made through granulate, is added the Borneolum Syntheticum fine powder, spray into the volatile oil that extracts by Lignum Dalbergiae Odoriferae and Lignum Santali Albi, by the capsule filler filling, make capsule behind the mixing.
Perhaps, preparation of the present invention is preferably made by following preparation method:
A) weight ratio of crude drug is: Radix Ginseng 3-10 part, Hirudo 3-11 part, Eupolyphaga Seu Steleophaga 5-10 part, Olibanum (system) 1-5 part, Radix Paeoniae Rubra 3-9 part, Lignum Dalbergiae Odoriferae 1-5 part, Lignum Santali Albi 1-5 part, Scorpio 3-9 part, Periostracum Cicadae 3-12 part, Scolopendra 1-3 part, Borneolum Syntheticum 1-7 part, Semen Ziziphi Spinosae (parched) 3-10 part;
B) pulverizing medicinal materials technology:
Scorpio, Hirudo, Scolopendra, Eupolyphaga Seu Steleophaga and five kinds of worm medicines of Periostracum Cicadae are prepared burden by prescription through the Olibanum (processed) that cleans, washes after handling the back and cleaning the process of preparing Chinese medicine, pulverized by pulverizer, the medicated powder fineness reaches more than 80 orders; Medicated powder behind the coarse powder carries out micronizing through various superfine communication techniques, makes the medicated powder mean diameter less than 100 μ m; Medical material to be pulverized is prepared burden after the cleaning, drying sterilization;
C) extract concentrated and drying process:
Reuse water extraction behind Lignum Dalbergiae Odoriferae and the Lignum Santali Albi elder generation extracting in water volatile oil, Radix Paeoniae Rubra and Semen Ziziphi Spinosae decoct with water, after the water extract filters, extractum to be condensed into; Radix Ginseng with ethanol extraction after, reuse water extraction, alcohol extract are condensed into alcohol-extracted extract after reclaiming ethanol, the water extract filter with all water extract mixings after be condensed into the water extracted immersing paste, extractum directly is spray dried to spray powder;
D) preparation process:
The superfine powder flour is added in the Fluidbedgranulatingdrier with step c) gained spray drying powder, sprays solvent again and make granule; The granule made through granulate, is added the Borneolum Syntheticum fine powder, spray into the volatile oil that extracts by Lignum Dalbergiae Odoriferae and Lignum Santali Albi, by the capsule filler filling, make capsule behind the mixing.
Chinese medicine composition of the present invention is made up of Radix Ginseng, Hirudo, Scolopendra, Scorpio, Eupolyphaga Seu Steleophaga, Periostracum Cicadae, Radix Paeoniae Rubra, Borneolum Syntheticum etc., has the effect of benefiting QI for activating blood circulation, disperse blood stasis and dredge collateral.Pharmacological research shows: Chinese medicine composition of the present invention has the impermeabilisation effect, can reduce whole blood viscosity, significantly improve vascular endothelial function, strengthen the elasticity that vein shrinks and increase wall of vein, improve the blood vessel wall venous pressure, thereby reach detumescence and alleviate the stagnant symptom of the vein stasis of blood.Simultaneously, can also increase peripheral vascular perfusion flow, the expansion blood capillary reduces intravascular pressure with the opening that increases capillary bed, alleviates edema in retinal edema and the blood vessel, increases the confession of arteria retina blood, improves retinal vein occlusion patient's vision.
The consumption of pharmaceutical composition of the present invention is converted to the weight of raw medicinal material, is each 0.8-3 gram, and take 2-4 every day, is preferably each 1.11-2.22 and restrains, and takes every day three times.
The specific embodiment
Embodiment 1:
A) the crude drug prescription is:
Radix Ginseng 39.6g Hirudo 72.6g Eupolyphaga Seu Steleophaga 46.2g Olibanum (system) 13.2g
Radix Paeoniae Rubra 33g Lignum Dalbergiae Odoriferae 13.2g Lignum Santali Albi 13.2g Scorpio 19.8g
Periostracum Cicadae 46.2g Scolopendra 6.6g Borneolum Syntheticum 33g Semen Ziziphi Spinosae (stir-fry) 33g;
B) pulverizing medicinal materials technology:
Scorpio, Hirudo, Scolopendra, Eupolyphaga Seu Steleophaga and five kinds of worm medicines of Periostracum Cicadae are prepared burden by prescription through the Olibanum (processed) that cleans, washes after handling the back and cleaning the process of preparing Chinese medicine, pulverized by pulverizer, the medicated powder fineness reaches more than 80 orders; Medicated powder behind the coarse powder carries out micronizing through various superfine communication techniques, makes the medicated powder mean diameter less than 30-40 μ m; Medical material to be pulverized is prepared burden after the cleaning, drying sterilization;
C) extract concentrated and drying process:
Reuse water extraction behind Lignum Dalbergiae Odoriferae and the Lignum Santali Albi elder generation extracting in water volatile oil, Radix Paeoniae Rubra and Semen Ziziphi Spinosae add suitable quantity of water and decoct secondary, and each 3 hours, merge the water extract, after the filtration, extractum to be condensed into; Radix Ginseng is with an amount of 70% ethanol extraction secondary, each 3 hours, merge extractive liquid,, reclaim ethanol to there not being the alcohol flavor, the reuse water extraction, it is 0.9～1.1 (60 ℃) alcohol-extracted extract that alcohol extract is condensed into relative density, is concentrated into the clear paste that relative density is 0.9～1.1 (60 ℃) behind the filtration of water extract and above-mentioned all water extract mixings, standby;
D) preparation process:
In Fluidbedgranulatingdrier, add the superfine powder flour, again the step c) gained is extracted extractum and spray into granulation; The granule made through granulate, is added the Borneolum Syntheticum fine powder, spray into the volatile oil that extracts by Lignum Dalbergiae Odoriferae and Lignum Santali Albi, by the capsule filler filling, make 1000 capsules behind the mixing.
Amount of drug of the present invention for each 2-4 grain, is taken three times every day.
For illustrating the therapeutic activity of Chinese medicine composition of the present invention to the retinal vein occlusion, carried out following clinical trial proving its curative effect with the capsule that makes by the foregoing description 1 method (to call medicine of the present invention in the following text), but it can not constitute any restriction to scope of the present invention.
Experimental example:
1 data and method
1.1 physical data
With 52 examples (72) clinical diagnosis is that RVO patient's completely random is divided into two groups, medicine group of the present invention (observation group), 37 of 27 examples, male 14 examples (20), women 13 examples (17); Retinal vein central authorities trunk blocks 7 examples (10), ischemia type 2 examples wherein, non-ischemia type 5 examples; Branch's vein obstruction 20 examples (27), ischemia type 6 examples wherein, non-ischemia type 14 examples; 23～68 years old age, average 55.5 ± 9.7 years old; The course of disease 3～90d, average 31.9 ± 23.8 days.35 of Radix Salviae Miltiorrhizae Injection group (matched group) (Shijiazhuang Shineway Pharmaceutical Co., Ltd's production) 25 examples, male 13 examples (19), women 12 examples (16) wherein retinal vein central authorities trunk are blocked 8 examples (9), ischemia type 3 examples wherein, non-ischemia type 6 examples; Branch's vein obstruction 17 examples (26) are ischemia type 8 examples wherein, non-ischemia type 18 examples; 21～69 years old age, average 54.8 ± 8.2 years old; The course of disease 1～90d, average 30.7 ± 24.2 days.Difference that two groups of patient ages, sex, the course of disease and obstructive position distribute that relatively there are no significant has comparability between two groups.
1.2 clinical retinopathy that diagnostic criteria is edited with reference to Huang Quanren [the Huang Quanren chief editor. clinical retinopathy is learned. Hefei: Anhui science and technology publishing house.1994,51～55] retinal vein occlusion diagnostic criteria:
(1) 1. the optical fundus microscopy is always done and is blocked: papilloedema. and the expansion of vein anfractuosity, the whole network film is hemorrhage.Edema.2. branch blocks: branch's vein anfractuosity expansion. and hemorrhage along pathological changes venous nethike embrane.
(2) 1. always do obstruction with end angiography: look the nipple fluorescence leakage. venous filling time delays. and wall dyes, seepage. hemorrhage covering fluorescence.2. branch blocks: branch's venous filling time delays. and wall dyes. seepage. hemorrhage covering fluorescence.
1.3 standard of including in: be diagnosed as the retinal vein occlusion; 21～70 years old age; Voluntary accepting treatment, and can cooperate and observe and the examiner.
1.4 exclusion standard: the age is at under-21 or more than 70 years old; Gestation or women breast-feeding their children; To this medicine allergy sufferers; Diabetics; Be associated with serious primary disease such as cardiovascular, liver, kidney and hemopoietic system and psychotic.
1.5 Therapeutic Method: 37 of observation group's 27 examples are all used Drug therapy of the present invention.Dosage and method: 4/time, 3 times/day, took continuously 30-90 days.Treat observe the curative effect after 30 days.35 of matched group 25 examples add 0.9% normal saline 250ml with Radix Salviae Miltiorrhizae Injection 20ml, intravenous drip 1 time/day, and 8 days is a course of treatment, after finishing each course of treatment, 3 courses of treatment are treated in drug withdrawal 2 days continuously.Two groups are aided with Drug therapys such as vitamin C, B family, vitamin E, inosine simultaneously, and it is rich to advise the patient to guard against food simultaneously, takes the low fat diet measure.
1.6 efficacy determination: vision situation of change, with the international standard visual acuity chart is examination criteria :≤0.1, with vision improve or go down 2 row or 2 row above be vision enhancement or decline,＜0.1, with the every increase and decrease 0.02 of vision or 0.02 above be that vision is promoted or decline, otherwise be no change.Be divided into 4 grades in conjunction with optical fundus and FFA check result:
Produce effects: vision is promoted, retinal hemorrhage basic absorption, new vessels complete obiteration, fluorescein ne-leakage;
Effectively: vision is promoted or is constant, and retinal hemorrhage partially absorbs, and new vessels disappears, and a little fluorescein seepage is still arranged;
Invalid: vision is constant, and retinal hemorrhage does not have obvious absorption, and new vessels does not have obviously and disappears, and still has the fluorescein seepage;
Regress: visual deterioration, retina are hemorrhage once more, the new vessels growth, and the fluorescein seepage increases the weight of.
1.7 statistical analysis: adopt SPSS10.0 software to carry out statistical analysis, enumeration data represents to adopt X 2 test with rate, and there is statistical significance P＜0.05 for difference.
2. result:
2.1 two groups of total relatively treatment group of curative effect total effective rates see Table 1 apparently higher than matched group (P＜0.05).
The table 1 liang efficacy result that group is total relatively
Annotate: compare with matched group,
*P＜0.05
2.2 untoward reaction: all do not find obvious toxic and side effects for two groups in treatment, hematuria routine, hepatic and renal function, Electrocardioscopy there is no tangible change before and after the treatment.Gastrointestinal reactions such as feeling sick appears in 2 routine patients, epigastrium burn feeling are not done any processing and spontaneous remission.
3 conclusions
This experimental result observation group is patient's eyesight improving after medication, and retinal hemorrhage absorbs and disappears, and the fluorescein seepage improves, and the total effective rate of treatment reaches 91.9%, and its curative effect obviously is better than Radix Salviae Miltiorrhizae Injection.Illustrate that medicine of the present invention has curative effect preferably to the retinal vein occlusion, can show the symptom of improving the high retinal vein occlusion.Its method is simple, safety, no obvious adverse reaction.
Claims (7)
1. the application of Chinese medicine composition in the medicine of the preparation treatment retinal vein occlusion is characterized in that this Chinese medicine composition is made by following bulk drugs:
Radix Ginseng 3-10 Hirudo 3-11 Eupolyphaga Seu Steleophaga 5-10 Olibanum (system) 1-5 Radix Paeoniae Rubra 3-9 Lignum Dalbergiae Odoriferae 1-5
Lignum Santali Albi 1-5 Scorpio 3-9 Periostracum Cicadae 3-12 Scolopendra 1-3 Borneolum Syntheticum 1-7 Semen Ziziphi Spinosae (stir-fry) 3-10.
2. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is made by following bulk drugs:
Radix Ginseng 6 Hirudo 10 Eupolyphaga Seu Steleophagas, 7 Olibanums (system) 2 Radix Paeoniae Rubra 5 Lignum Dalbergiae Odoriferaes 2
Lignum Santali Albi 2 Scorpios 7 Periostracum Cicadaes 7 Scolopendra 1 Borneolum Syntheticum, 5 Semen Ziziphi Spinosaes (stir-fry) 5.
3. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is made by following bulk drugs:
Radix Ginseng 10 Hirudo 8 Eupolyphaga Seu Steleophagas, 7 Olibanums (system) 2 Radix Paeoniae Rubra 5 Lignum Dalbergiae Odoriferaes 2
Lignum Santali Albi 2 Scorpios 9 Periostracum Cicadaes 7 Scolopendra 1 Borneolum Syntheticum, 5 Semen Ziziphi Spinosaes (stir-fry) 5.
4. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is made by following bulk drugs:
Radix Ginseng 6 Hirudo 11 Eupolyphaga Seu Steleophagas, 7 Olibanums (system) 2 Radix Paeoniae Rubra 5 Lignum Dalbergiae Odoriferaes 2
Lignum Santali Albi 2 Scorpios 3 Periostracum Cicadaes 7 Scolopendra 1 Borneolum Syntheticum, 5 Semen Ziziphi Spinosaes (stir-fry) 5.
5. as each described application among the claim 1-4, it is characterized in that the active component of described Chinese medicine composition is made up of following ingredients:
The a mean diameter is less than Scorpio, Hirudo, Scolopendra, Eupolyphaga Seu Steleophaga, Periostracum Cicadae and Olibanum (system) medicated powder of 100 μ m;
B Borneolum Syntheticum medicated powder;
The volatile oil that c is extracted by Lignum Dalbergiae Odoriferae and Lignum Santali Albi;
The alcohol-extracted extract of the alcohol extract of d Radix Ginseng after after concentrating with ethanol extraction;
The water extracted immersing paste that is condensed into behind the water extract after the Lignum Dalbergiae Odoriferae behind the e extraction composition c and water extract, Radix Paeoniae Rubra and the Semen Ziziphi Spinosae (stir-fry) of Lignum Santali Albi medicinal residues decoct with water and the water extract filtration of the medicine residues of Radix Ginseng after the extraction ingredient d, the mixing.
6. as each described application among the claim 1-4, it is characterized in that this Chinese medicine composition is capsule, tablet, granule, powder, oral liquid or pill as the pharmaceutical preparation of active component.
7, as each described application among the claim 1-4, it is characterized in that the application of this Chinese medicine composition in the medicine of preparation raising retinal vein occlusion patient's vision.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101522460A CN101390973A (en) | 2007-09-20 | 2007-09-20 | Use of traditional Chinese medicine in preparing medicine for treating retinal vein obstruction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101522460A CN101390973A (en) | 2007-09-20 | 2007-09-20 | Use of traditional Chinese medicine in preparing medicine for treating retinal vein obstruction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101390973A true CN101390973A (en) | 2009-03-25 |
Family
ID=40491614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101522460A Pending CN101390973A (en) | 2007-09-20 | 2007-09-20 | Use of traditional Chinese medicine in preparing medicine for treating retinal vein obstruction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101390973A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101797348B (en) * | 2009-12-25 | 2012-03-28 | 西安碑林药业股份有限公司 | Traditional Chinese medicine for treating proliferative vitreoretinopathy |
| CN105031130A (en) * | 2015-08-25 | 2015-11-11 | 何萍萍 | Traditional Chinese medicine for treating central retinal vein occlusion |
-
2007
- 2007-09-20 CN CNA2007101522460A patent/CN101390973A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101797348B (en) * | 2009-12-25 | 2012-03-28 | 西安碑林药业股份有限公司 | Traditional Chinese medicine for treating proliferative vitreoretinopathy |
| CN105031130A (en) * | 2015-08-25 | 2015-11-11 | 何萍萍 | Traditional Chinese medicine for treating central retinal vein occlusion |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101683405B (en) | Application of a traditional Chinese medicine composition in preparation of medicament for treating and preventing brain stroke | |
| CN101780227B (en) | Traditional Chinese medicine composition for treating acute stroke and preparation method thereof | |
| CN101390973A (en) | Use of traditional Chinese medicine in preparing medicine for treating retinal vein obstruction | |
| CN101683406B (en) | Application of a traditional Chinese medicine composition in preparation of medicament for treating and preventing hypertension | |
| CN101632813B (en) | Novel traditional Chinese medicine composition for treating diabetes class eyeground haemorrhage and preparation method thereof | |
| CN101716248B (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN101632726B (en) | Application of Chinese medicinal composition in preparing medicament for treating blood vessel micro-embolization | |
| CN101632727B (en) | Application of Chinese medicinal composition in preparing medicament for treating pulmonary hypertension | |
| CN103623139A (en) | Application of traditional Chinese medicine composition to prepare medicaments for treating central serous chorioretinopathy | |
| CN101632729B (en) | Application of Chinese medicinal composition in preparing medicament for treating involution syndrome | |
| CN105213887A (en) | One is used for the treatment of glaucomatous Chinese medicine composition | |
| CN104306579B (en) | A kind of Chinese medicine for treating deficiency of yin and stagnation of blood diabetic retinopathy and preparation method and application | |
| CN101612217B (en) | Application of Chinese medicinal composition in preparation of medicaments for treating central serous chorioretinopathy | |
| CN107753738A (en) | A kind of application of Chinese medicine composition in the medicine for preparing treatment pulmonary hypertension | |
| CN102370735B (en) | Application of traditional Chinese medicinal composition in preparation of medicament for treating polycythemia | |
| CN101632728B (en) | Application of Chinese medicinal composition in preparing medicament for protecting blood brain barrier | |
| CN101683458B (en) | Application of a traditional Chinese medicine composition in preparation of medicament for treating vertigo | |
| CN101744905B (en) | Applications of Chinese medicinal composition in preparation of medicament for treating pulmonary heart disease | |
| CN102178758A (en) | Medicament for treating peripheral nerve of diabetes | |
| CN106177331A (en) | A kind of Chinese medicine treating hypertension | |
| CN105456553A (en) | Application of Chinese medicinal composition in preparation of drugs treating ocular ischemic syndrome | |
| CN101757153B (en) | Application of traditional Chinese medicine composition in preparation of medicines for treating kidney deficiency blood stasis type erectile dysfunction | |
| CN101590173A (en) | The application of a kind of Chinese medicine composition in the medicine of preparation treatment hypertensive cerebral hemorrhage | |
| CN102451248B (en) | Application of traditional Chinese medicine composition in preparation of medicament for treating diabetic neuropathy | |
| CN105456554B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating retinal vein obstruction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20090325 |